By brewing with 100 percent quinoa, Meli is ‘giving beer a wellness makeover'
Get Winter Soup Club
A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
'The only issue was that the beer in Peru contained barley, and I was reducing gluten from my diet.'
Advertisement
Oster set out to brew a 100 percent quinoa beer.
'The first challenge we encountered at homebrew-scale was what type of quinoa to use. Quinoa exists in red, black, and white varieties, and quinoa grown in one part of the world has completely different nutritional features than quinoa from other parts of the world. So, identifying a quinoa that both tasted good and efficiently produced an alcoholic beverage was a challenge,' says Oster.
Advertisement
It took more than 20 test batches to brew a beer that satisfied those requirements. And then another challenge arose: because quinoa is such a small grain, adapting a recipe to fit commercial brewing equipment wasn't straightforward. It took nearly 100 formulations, according to Oster, to get it right.
Brew Theory Brewery in Lowell currently brews Meli. The beer is gluten-free, has zero sugar, and contains the proteins and essential vitamins and minerals such as iron and B6 typically found in quinoa. A can of Meli even contains about 7 percent of your daily potassium.
One noticeable aspect of the beer is that it tastes a little spicy, the result of using an herbaceous grain rather than the typical barley. Meli is light and crisp, like Oster says, and should make an interesting pairing with all kinds of food.
Oster is 'committed to winning in our own backyard,' meaning Massachusetts. Meli beer is available at select restaurants including Uni, Catalyst, Alma Nove, and Shy Bird, as well as at Trader Joe's and Whole Foods.
Gary Dzen can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Dominion Post
26-07-2025
- Dominion Post
Mon Medical Center participates in trial for device that could revolutionize Afib treatment
dbeard@ MORGANTOWN – Vandalia Health Mon Medical Center is participating in a clinical trial that could forever change how patients with atrial fibrillation are treated. The trial is called Catalyst, for the Abbott Medical Devices Amplatzer Amulet Left Atrial Appendage Occluder. The Amulet is already in use for Afib patients who can't use oral anticoagulants (blood thinners), said Dr. Wissam Gharib, who is leading the trial at Mon Medical. But this could broaden its use to all Afib patients, he said. This trial, he said, follows a similar trial, called Champion-AF, for the Watchman device by Boston Scientific. If the trials are successful, he said, 'This will be a paradigm shift in how we treat patients.' Abbott describes Afib as irregular electrical impulses in the upper chambers of the heart that cause those chambers to fibrillate, or quiver. This results in an irregular and frequently rapid heart rate that affects the heart's ability to pump blood, allowing blood to pool and collect in the left atrial appendage. Abbott explains that there is a muscular pouch connected to the left atrium of the heart called the left atrial appendage. If the blood clots are pumped from the appendage out into the body, the clots may flow to the brain and lead to stroke. The Amulet and the Watchman are both inserted via catheter to seal off the left atrial appendage. Gharib explains that patients diagnosed with Afib are first treated with blood thinners. For those who can't tolerate the medications, the Amulet and the Watchman provide an alternative approved by the FDA. The Catalyst and Champion trials, he said, aim to learn if the devices function as well as blood thinners and could be offered as an immediate alternative to blood thinners for everyone. Blood thinners, he said, carry various costs: among them are bleeding, clearances for dental work, pausing for surgical procedures, and the financial costs of being on the medications for life. If the trials prove the devices are as good as a blood thinner, a patient will have a choice. 'That's where these two trials are really pivotal in how we treat atrial fibrillation,' he said. The Champion trial – conducted at 141 locations, including Mon Medical – is complete and waiting on five-year results. Catalyst – being conducted at 132 locations, including Mon Medical – under way. Gharib said they have performed a number of procedures already and are still enrolling participants. He expects this portion of the trial will conclude at the end of the year. Volunteers are split into two groups: half get the Amulet, half get blood thinners. Participants have regular follow-up appointments for the five-year study period. Patients will know within a few weeks if the Amulet is working, he said, but the five-year period monitors long-term results and effects.
Business Wire
10-07-2025
- Business Wire
O'Neill Vintners & Distillers Launch Catalyst Energy Drink, Entering the Functional Beverage Market
LARKSPUR, Calif.--(BUSINESS WIRE)-- O'Neill Vintners & Distillers, a Certified B Corporation, boldly enters the fast-growing functional beverage market with the launch of Catalyst, an energy drink designed for today's health-conscious consumer. This strategic expansion marks a pivotal moment for the family-owned organization, evolving its portfolio beyond wine and spirits to enter the intersection of energy drinks and functional beverage. Catalyst is entering this market to meet evolving consumer preferences for healthier, great-tasting energy drinks that combine moderate caffeine with low-to-no sugar and added natural vitamins and supplements. Share The U.S. functional beverage market is seeing strong growth, particularly in the energy and sports drinks categories, with the segment expanding by 15.4% this year. Catalyst is entering this market to meet evolving consumer preferences for healthier, great-tasting energy drinks that combine moderate caffeine with low-to-no sugar and added natural vitamins and supplements. Catalyst aligns with these preferences, offering 120mg of caffeine, 10 calories, zero sugar and no artificial sweeteners, colors, or flavors. Catalyst delivers sustained performance, without the sugar load or 'spike and crash' effect, through an innovative formula of premium nootropics that work synergistically to sharpen focus, enhance mental clarity, and sustain cognitive performance. Powered by plant-based caffeine and fortified with essential vitamins B12 and B6, Catalyst also supports elevated metabolism and natural energy production. 'Our goal with Catalyst is to offer an energy drink that doesn't compromise on health, flavor, or efficacy,' said Jeff O'Neill, Founder and CEO of O'Neill Vintners & Distillers. 'We're proud to introduce a product that embodies our commitment to innovation and quality.' Housed in a sleek, modern can, Catalyst is available in six flavors, SuperBerry, PomPower, Grapefruit Frost, Fruit Fusion, Citrus Spark and Orange Dream, at a competitive price of $32.99 for a 12-pack and $2.99 for a single 12-ounce can. Catalyst can be purchased online at or at select retailers. About O'Neill Vintners & Distillers O'Neill Vintners & Distillers, a Certified B Corporation, is a family-owned, vertically integrated wine and spirits company dedicated to crafting exceptional wines and spirits while setting a new standard for sustainability in the industry. Founded in 2004 by visionary Jeff O'Neill, the company has emerged as a true leader in environmental stewardship—proving that scale and sustainability can go hand in hand. O'Neill has earned some of the highest honors in the field, including B Corp Certification, Regenerative Organic Certified® status, and the prestigious Green Medal Leader Award from the California Wine Institute. These accolades reflect not only a deep commitment to regenerative farming and climate-smart practices, but also a bold vision for the future of wine and spirits. With winery estates in Sonoma and Paso Robles and a winery facility in Parlier, O'Neill's diverse portfolio includes Ram's Gate Winery, Robert Hall Winery, Line 39, Wines of Substance, FitVine Wine, Harken Chardonnay, Rabble Wine Company, Charles Woodson's Intercept, No. 209 Gin, and BrandyLab. To learn more, visit
Business Insider
24-06-2025
- Business Insider
Corcept says Catalyst trial met primary endpoint
Corcept Therapeutics (CORT) Incorporated presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym in patients with hypercortisolism and difficult-to-control type 2 diabetes at the American Diabetes Association's 85th Scientific Sessions. CATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo. Of the 91 patients in the treatment group, 65received at least 600mg of Korlym and 28 received 900mg. Patients who received 900mg of Korlym had an improvement in HbA1c of 2.01 percent, compared to a 0.16 percent decrease in patients who received placebo. The trial also met its secondary endpoints, as patients who received Korlym exhibited significantly reduced body weight and waist circumference, compared to patients who received placebo. Patients receiving Korlym achieved these improvements despite reducing or discontinuing their glucose-lowering medications. Adverse events in CATALYST were manageable and consistent with Korlym's known safety profile. The most common adverse events were hypokalemia, fatigue and nausea.
